<PAGE>   1
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 10-Q

                QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                  FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1999

                        COMMISSION FILE NUMBER: 000-24539

                              ECLIPSYS CORPORATION
             (Exact name of registrant as specified in its charter)

DELAWARE                                          65-0632092
(State of Incorporation)                          (IRS Employer Identification
                                                  Number)

                            777 East Atlantic Avenue
                                    Suite 200
                              Delray Beach, Florida
                                      33483
                    (Address of principal executive offices)

                                 (561)-243-1440
                        (Telephone number of registrant)




        Indicate by check mark whether the registrant (1) has filed all reports
        required to be filed by Section 13 or 15(d) of the Securities Exchange
        Act of 1934 during the preceding 12 months (or for such shorter period
        that the registrant was required to file such reports) and (2) has been
        subject to such filing for the past 90 days. Yes X  No 
                                                        ---    ----
        Indicate the number of shares outstanding of each of the issuer's
        classes of common stock as of the latest practicable date.

<TABLE>
<CAPTION>
            Class                                  Shares outstanding as of April 30,1999
            -----                                  --------------------------------------

<S>                                                          <C>       
Common Stock, $.01 par value                                    31,509,283
Non-voting Common Stock, $.01 par value                            597,621
</TABLE>


<PAGE>   2

                              ECLIPSYS CORPORATION

                                    FORM 10-Q

                      FOR THE QUARTER ENDED MARCH 31, 1999

                                      INDEX

<TABLE>
<CAPTION>
        PART I.       Financial Information

<S>                   <C>
        Item 1.       Condensed Consolidated Balance Sheets (unaudited) - As of March 31, 1999 and December 31, 1998

                      Condensed Consolidated Statements of Operations (unaudited) - For the Three Months ended 
                      March 31, 1999 and 1998

                      Condensed Consolidated Statements of Cash Flows (unaudited) - For the Three Months ended 
                      March 31, 1999 and 1998

                      Notes to Condensed Consolidated Financial Statements (unaudited) - For the Three Months ended 
                      March 31, 1999 and 1998

        Item 2.       Management's Discussion and Analysis of Financial Condition and Results of Operations


        PART II.      Other Information

        Item 6.       Exhibits and Reports on Form 8-K
</TABLE>


<PAGE>   3
PART I.
ITEM 1.

                              ECLISPSYS CORPORATION
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                    AS OF MARCH 31, 1999 AND DECEMBER 31, 1998
                                  (IN THOUSANDS)
                                   (UNAUDITED)


<TABLE>
<CAPTION>
 ASSETS                                         MARCH 31, 1999     DECEMBER 31, 1998
                                               ----------------   ----------------
<S>                                             <C>                <C>     
 Current assets:
 Cash and cash equivalents                            $ 50,310           $ 37,983
 Investments                                                 -             17,003
 Accounts receivable, net                               63,073             57,924
 Inventory                                                 578                517
 Other current assets                                   10,870             10,004
                                               ----------------   ----------------
 TOTAL CURRENT ASSETS                                  124,831            123,431

 Fixed assets, net                                      12,633             12,349
 Capitalized software development costs, net             6,052              5,248
 Acquired technology, net                               56,814             43,318
 Intangible assets, net                                 23,765             25,928
 Other assets                                            5,676              6,060

                                               ----------------   ----------------
 TOTAL ASSETS                                        $ 229,771          $ 216,334
                                               ================   ================

 LIABILITIES AND SHAREHOLDERS' EQUITY
 Current liabilities:
 Deferred revenue                                     $ 53,810           $ 51,366
 Current portion of long-term debt                      20,000                  -
 Other current liabilities                              44,518             47,700
                                               ----------------   ----------------
 TOTAL CURRENT LIABILITIES                             118,328             99,066

 Deferred revenue                                       10,607             16,700
 Other long-term liabilities                             3,752              3,756

 SHAREHOLDERS' EQUITY
 Common stock                                              318                311
 Common stock warrant                                      395                395
 Unearned stock compensation                              (160)              (178)
 Additional paid-in capital                            243,282            241,929
 Accumulated other comprehensive income                    203                 44
 Accumulated deficit                                  (146,954)          (145,689)
                                               ----------------   ----------------
 TOTAL SHAREHOLDERS' EQUITY                             97,084             96,812


                                               ----------------   ----------------
 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY          $ 229,771          $ 216,334
                                               ================   ================
</TABLE>

    THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE UNAUDITED CONDENSED
                       CONSOLIDATED FINANCIAL STATEMENTS

<PAGE>   4

                                        ECLIPSYS CORPORATION
                          CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                         FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND 1998
                         (IN THOUSANDS EXCEPT SHARE AND PER SHARE AMOUNTS)
                                            (UNAUDITED)

<TABLE>
<CAPTION>
                                                             THREE MONTHS ENDED
                                                                  MARCH 31,
                                                          --------------------------
     REVENUES                                                 1999         1998
                                                             ------       ------ 
<S>                                                      <C>           <C>       
     Systems and services                                    $ 48,435      $ 34,852
     Hardware                                                   5,498         2,290
                                                          --------------------------
     TOTAL REVENUES                                            53,933        37,142
                                                          --------------------------

     COSTS AND EXPENSES
     Cost of systems and services revenues                     27,302        21,006
     Cost of hardware revenues                                  4,670         1,977
     Marketing and sales                                        7,418         6,413
     Research and development                                   9,097         7,753
     General and administrative                                 2,720         2,619
     Depreciation and amortization                              3,814         2,963
     Write off of MSA                                               -         7,193
     Pooling costs                                                614             -
                                                          --------------------------
     TOTAL COSTS AND EXPENSES                                  55,635        49,924
                                                          --------------------------

                                                          --------------------------
     LOSS FROM OPERATIONS                                      (1,702)      (12,782)
                                                          --------------------------

     Interest income, net                                        (437)         (435)

     LOSS BEFORE INCOME TAXES                                  (1,265)      (12,347)
     PROVISION FOR INCOME TAXES                                     -         1,921
                                                          --------------------------
 
     NET LOSS                                                  (1,265)      (14,268)
                                                          --------------------------

      DIVIDENDS AND ACCRETION ON MANDATORILY
      REDEEMABLE PREFERRED STOCK                                    -        (1,335)

                                                          --------------------------

      NET LOSS AVAILABLE TO COMMON SHAREHOLDERS              $ (1,265)    $ (15,603)
                                                          --------------------------

      BASIC AND DILUTED NET LOSS PER COMMON SHARE             $ (0.04)      $ (1.03)
                                                          --------------------------

      WEIGHTED AVERAGE COMMON SHARES OUTSTANDING           31,315,000    15,112,000
                                                          --------------------------
</TABLE>


    THE ACCOMPANYING NOTES ARE AN INTEGRAL PART OF THESE UNAUDITED CONDENSED
                       CONSOLIDATED FINANCIAL STATEMENTS


<PAGE>   5
                              ECLIPSYS CORPORATION
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
               FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND 1998
                                 (IN THOUSANDS)
                                   (UNAUDITED)

<TABLE>
<CAPTION>
                                                                                    Three Months ended March 31,
                                                                                    ----------------------------
                                                                                       1999            1998
                                                                                     --------        --------
<S>                                                                              <C>             <C>      
Operating Activities
Net Loss                                                                             $ (1,265)       $(14,268)
Adjustments to reconcile net loss to net cash
provided by operating activities
              Depreciation and amortization                                             9,828           7,466
              Provision for bad debts                                                     285             225
              Tax benefit of stock option exercises                                         -              15
              Write off of MSA                                                              -           7,193
              Stock compensation expense                                                   18              18
              Changes in operating assets and liabilities, net of acquisitions
              Accounts receivable                                                       3,165           2,341
              Inventory                                                                   (61)            200
              Other current assets                                                       (117)          1,958
              Other assets                                                                223            (308)
              Deferred revenue                                                         (6,726)          8,137
              Other current liabilities                                                (4,039)          1,970
              Other liabilities                                                            (4)            (13)
                                                                                     --------        --------
                          Total adjustments to reconcile net loss to net
                          cash provided by operating activities                         2,572          29,202
                                                                                     --------        --------
                               Net cash provided by operating activities                1,307          14,934
                                                                                     --------        --------

Investing Activities
Purchase of fixed assets, net                                                          (1,269)         (1,888)
Capitalized software development costs                                                 (1,233)         (1,071)
Acquisitions, net of cash acquired                                                    (25,000)              -
Changes in other assets                                                                     -         (16,000)
                                                                                     --------        --------
                               Net cash used in investing activities                  (27,502)        (18,959)
                                                                                     --------        --------

Financing Activities
Borrowings under line-of-credit                                                        20,000           9,000
Payments on borrowings under line-of-credit                                                 -          (9,000)
Exercise of stock options                                                                 811             959
Sale of preferred stock                                                                     -           9,000
Employee stock purchase plan                                                              549               -

                                                                                     --------        --------
                               Net cash provided by financing activities               21,360           9,959
                                                                                     --------        --------

Effect of exchange rate changes on cash and
     cash equivalents                                                                     159              11
                                                                                     --------        --------

Net (decrease) increase in cash and cash equivalents                                   (4,676)          5,945

Cash and cash equivalents, beginning of period                                         54,986          63,414
                                                                                     --------        --------
Cash and cash equivalents, end of period                                             $ 50,310        $ 69,359
                                                                                     --------        --------
</TABLE>




    The accompanying notes are an integral part to these unaudited condensed
                       consolidated financial statements


<PAGE>   6


                              ECLIPSYS CORPORATION
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
          FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND MARCH 31, 1998
                                   (UNAUDITED)

1.      BASIS OF PRESENTATION

        The condensed consolidated financial statements include all adjustments
        that, in the opinion of management, are necessary for a fair
        presentation of the results for the periods presented. All such
        adjustments are considered of normal recurring nature. Quarterly results
        of operations are not necessarily indicative of annual results.

        Effective December 31, 1998, Eclipsys Corporation ("the Company")
        completed a merger with Transition Systems, Inc. ("Transition"). The
        merger was accounted for as a pooling of interests and, accordingly, the
        condensed consolidated financial statements have been retroactively
        restated as if the Transition merger had occurred as of the beginning of
        the earliest period presented.

        Effective February 17, 1999, the Company completed a merger with
        PowerCenter Systems, Inc. ("PCS"). The merger was accounted for as a
        pooling of interests and, accordingly, the condensed consolidated
        financial statements have been retroactively restated as if the PCS
        merger had occurred as of the beginning of the earliest period
        presented.

        Certain financial information and footnote disclosures normally included
        in financial statements prepared in accordance with generally accepted
        accounting principles have been condensed or omitted. These unaudited
        condensed consolidated financial statements should be read in
        conjunction with the consolidated financial statements and the notes
        thereto included in the Company's Annual Report on Form 10-K dated March
        26, 1999.

        Certain prior year amounts have been reclassified to conform to the
        current year presentation in the accompanying condensed consolidated
        financial statements.

2.      ACQUISITIONS

        As discussed in Note 1, effective February 17, 1999, the Company
        completed a merger with PCS for total consideration of approximately $35
        million. PCS provides enterprise resource planning software throughout
        the healthcare industry.

        As discussed in Note 1 the Transition and PCS acquisitions were
        accounted for as pooling of interests, accordingly, all prior period
        amounts have been restated. A reconciliation between revenue and net
        loss as previously reported by the Company and as restated (unaudited)
        is as follows:

<TABLE>
<CAPTION>
                                             For the three
                                             months ended
        Revenue:                             March 31, 1998
<S>                                         <C>     
               As previously reported       $ 29,295
               Transition                      7,730
               PCS                               117
                                            -------- 
               As restated                  $ 37,142
        Net Loss:
               As previously reported       $(11,610)
               Transition                     (1,964)
               PCS                              (694)
                                            -------- 
               As restated                  $(14,268)
                                            -------- 
                                            -------- 
</TABLE>



<PAGE>   7


                              ECLIPSYS CORPORATION
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
          FOR THE THREE MONTHS ENDED MARCH 31, 1999 AND MARCH 31, 1998
                                   (UNAUDITED)

        Effective March 31, 1999, the Company acquired the common stock of
        Intelus Corporation ("Intelus") and Med Data Systems, Inc. ("Med Data"),
        both wholly owned subsidiaries of Sungard Data Systems, Inc. for total
        consideration of $25 million in cash. The acquired entities both provide
        document imaging technology and workflow solutions to entities
        throughout the healthcare industry. The acquisition was accounted for as
        a purchase and, accordingly, the purchase price was allocated based on
        the fair value of the net assets acquired.

        Unaudited pro forma results of operations as if the aforementioned
        acquisitions had occurred on January 1, 1998 is as follows (in thousands
        except per share data):

<TABLE>
<CAPTION>
                                         Three months ended
                                               March 31,
                                         1999              1998
                                    ----------------------------
<S>                                    <C>             <C>     
Revenues                               $ 45,401        $ 57,424
Net loss                                (17,969)         (1,704)
Basic and diluted loss per share       $  (1.16)       $  (0.05)
</TABLE>


3.      LONG-TERM DEBT

        As discussed in Note 2, on March 31, 1999, the Company acquired the
        common stock of Intelus and Med Data for total consideration of $25
        million in cash. In connection with the transaction, the Company
        borrowed $20 million under its $50 million credit facility.

4.      POOLING COSTS

        Included in operating activities on the accompanying condensed
        consolidated statement of cash flows for the quarter ended March 31,
        1999 are $722,000 of costs paid related to the poolings of Transition
        and PCS.



<PAGE>   8



        PART I.
        ITEM 2.

        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
                              RESULTS OF OPERATIONS

        This report contains forward-looking statements. For this purpose, any
        statements contained herein that are not statements of historical fact
        may be deemed to be forward-looking statements. Without limiting the
        foregoing, the words "believes," "anticipates," "plans," "expects,"
        "intends," and similar expressions are intended to identify
        forward-looking statements. The important factors discussed under the
        caption "Certain Factors that May Affect Future Operating Results/Risk
        Factors," presented from time to time in the Company's filings with the
        Securities and Exchange Commission, among others, could cause actual
        results to differ materially from those indicated by forward-looking
        statements made herein. The Company undertakes no obligation to publicly
        update or revise any forward-looking statements, whether as a result of
        new information, future events or otherwise.

        OVERVIEW

        Eclipsys Corporation ("Eclipsys" or "the Company") is a healthcare
        information technology company delivering solutions that enable
        healthcare providers to achieve improved clinical, financial and
        administrative outcomes. The Company offers an integrated suite of core
        products in five critical areas - clinical management, access
        management, patient financial management, strategic decision support and
        integration. These products can be purchased in combination to provide
        an enterprise-wide solution or individually to address specific needs.
        Eclipsys' products have been designed specifically to deliver a
        measurable impact on outcomes, enabling Eclipsys' customers to quantify
        clinical benefits and return on investment in a precise and timely
        manner. Eclipsys' products can be integrated with a customer's existing
        information systems, which Eclipsys believes reduces overall cost of
        ownership and increases the attractiveness of its products. Eclipsys
        also provides outsourcing, remote processing and networking services to
        assist customers in meeting their healthcare information technology
        requirements. Eclipsys markets its products primarily to large
        hospitals, academic medical centers and integrated health networks. To
        provide direct and sustained customer contact, Eclipsys maintains
        decentralized sales, implementation and customer support teams in each
        of its eight North American regions.

        The Company was formed in December 1995 and has grown primarily through
        a series of acquisitions, all completed since January 1997. The first
        three acquisitions were accounted for utilizing the purchase method of
        accounting and, accordingly, Eclipsys' financial statements reflect the
        results of these businesses from the date acquired. These acquisitions
        were (1) the acquisition of ALLTEL Healthcare Information Services, Inc.
        ("Alltel") in January 1997, (2) the acquisition of SDK Medical Computer
        Services Corporation ("SDK") in June 1997 and (3) the acquisition of the
        North American operations of Emtek Healthcare Systems, a division of
        Motorola, Inc. ("Emtek"), in January 1998. The next two acquisitions
        were accounted for utilizing the pooling of interests method of
        accounting and, accordingly, Eclipsys' financial statements have been
        retroactively restated as if the transactions had occurred as of the
        earliest period presented. These acquisitions were (1) a merger with
        Transition Systems, Inc. ("Transition"), effective December 31, 1998,
        and (2) a merger with PowerCenter Systems, Inc. ("PCS"), effective
        February 17, 1999. Additionally, Transition had acquired HealthVISION,
        Inc. ("HealthVISION") in December 1998, shortly before the closing of
        the Eclipsys' acquisition of Transition. The HealthVISION acquisition
        was accounted for as a purchase and, accordingly, Eclipsys' financial
        statements reflect the results of the business from the date acquired.
        Finally, the purchase of Intelus Corporation and Med Data Systems, Inc.,
        both wholly owned subsidiaries of Sungard Data Systems, Inc., was
        completed on March 31, 1999 and was accounted for as a 


<PAGE>   9

        purchase and, accordingly, Eclipsys' financial statements will reflect
        the results of these businesses from the date acquired.

        RESULTS OF OPERATIONS

        SUMMARY

        Total revenues for the quarter ended March 31, 1999 increased 45% to
        $53.9 million compared with $37.1 million for the first quarter 1998.

        Total costs and expenses for the quarter ended March 31, 1999 increased
        11% compared to the same period in 1998.

        These changes in revenues and expenses combined to decrease net loss for
        the quarter ended March 31, 1999 by 91% to ($1.3) million compared to
        the same period in 1998.

        Included in the reported quarterly net losses were acquisition related
        amortization of intangible assets and certain non-recurring charges
        recorded in connection with the acquisitions of $8.1 million in the
        first quarter 1999 and $12.5 million in the first quarter 1998.

        REVENUES

        System and services revenues increased 39% to $48.4 million for the
        first quarter of 1999 compared to the same period in 1998. Contributing
        to this increase was the inclusion of the results of operations of Emtek
        and HealthVISION during first quarter 1999, as well as new contracted
        business during 1998 and 1997. The increase in new contracted business
        was a result of increased marketing efforts related to the regional
        re-alignment of the Company's operations completed in 1997 and the
        successful integration of the acquisitions.

        Hardware revenues increased 140% to $5.5 million for the first quarter
        of 1999 compared to the same period in 1998. The increase was primarily
        due to increased volume as a result of the acquisitions and new
        contracted business.

        EXPENSES

        Total cost of revenues increased 39% for the first quarter of 1999
        compared to the same period in 1998. Increased costs of system, services
        and hardware associated with the growth in sales were offset by a
        reduction of certain expenses and realization of cost savings as a
        result of the integration of the acquisitions.

        Marketing and sales expenses increased 16% for the first quarter of 1999
        compared to the same period in 1998. The increase was primarily due to
        the addition of marketing and direct sales personnel following the
        acquisitions and the continued hiring of sales people.

        Total expenditures for research and development, including both
        capitalized and non-capitalized expenses increased 17% to $10.3 million
        for the first quarter 1999 compared to the same period in 1998. The
        increase was due primarily to the acquisitions and the continued
        development of an enterprise-wide, client server platform solution.
        Research and development expenses capitalized for the first quarter of
        1999 increased $162,000 compared to the same period in 1998. Increased
        capitalization was primarily the result of expenditures related to the
        development of an enterprise-wide, client server platform solution.

        General and administrative expenses increased 4% for the first quarter
        of 1999 compared to the same period in 1998. The increase was primarily
        due to the addition of administrative and finance personnel following
        the acquisitions.
<PAGE>   10

        Depreciation and amortization increased 29% for the first quarter of
        1999 compared to the same period in 1998. The increase for the quarter
        is primarily the result of an increase in goodwill amortization as a
        result of the HealthVISION acquisition.

        ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT

        In connection with the Alltel, SDK and HealthVISION acquisitions, the
        Company wrote off acquired in-process research and development totaling
        $92.2 million and $7.0 million in 1997 and $2.4 million in 1998,
        respectively. These amounts were expensed as non-recurring charges on
        the respective acquisition dates. The Company continues to believe that
        the acquired in-process research and development will be successfully
        developed, but there can be no assurance that commercial viability of
        these products will be achieved.

        The value of the acquired in-process research and development was
        determined by estimating the projected net cash flows related to such
        products, including costs to complete the development of the technology
        and the future revenues to be earned upon commercialization of the
        products. These cash flows were discounted back to their net present
        value. The resulting projected net cash flows from such projects were
        based on management's estimates of revenues and operating profits
        related to such projects.

        Through March 31, 1999, revenues and operating profit attributable to
        acquired in-process research and development have not materially
        differed from the projections used in determining its value, except for,
        as previously reported, the timing of one outsourcing contract.
        Management continues to believe the projections used reasonably estimate
        the future benefits attributable to the acquired in-process research and
        development. However, no assurance can be given that deviations from
        these projections will not occur.

        YEAR 2000 ISSUES

        Eclipsys has a Year 2000 Committee whose task is to evaluate the
        Company's Year 2000 readiness for both internal and external management
        information systems, recommend a plan of action to minimize disruption
        and execute the Company's Year 2000 plan. The Committee has developed a
        comprehensive Year 2000 Plan. The Year 2000 Plan covers all significant
        internal and external management information systems.

        Eclipsys believes that all of its internal management information
        systems are currently Year 2000 compliant and, accordingly, does not
        anticipate any significant expenditures to remediate or replace existing
        internal-use systems.

        With the exception of the Transition for Quality product (for which the
        Company expects to release a fully Year 2000 compliant version in 1999),
        all of the products currently offered by Eclipsys are Year 2000
        compliant. Some of the products previously sold by Alltel and Emtek and
        installed in Eclipsys' customer base are not Year 2000 compliant.
        Eclipsys has developed and tested solutions for these non-compliant,
        installed products.

        In addition, because Eclipsys' products are often interfaced with a
        customer's existing third-party applications and certain Eclipsys'
        products include software licensed from third-party vendors, Eclipsys'
        products may experience difficulties interfacing with third-party,
        non-compliant applications. Based on currently available information,
        Eclipsys does not expect the cost of compliance related to interactions
        with non-compliant, third-party systems to be material.

        Unexpected difficulties in implementing Year 2000 solutions for the
        installed Alltel or Emtek products or difficulties in interfacing with
        third-party products could adversely effect the Company.
<PAGE>   11

        Apprehension in the marketplace over Year 2000 compliance issues may
        lead businesses, including customers of the Company, to defer
        significant capital investments in information technology programs and
        software. They could elect to defer those investments either because
        they decide to focus their capital budgets on the expenditures necessary
        to bring their own existing systems into compliance or because they wish
        to purchase only software with a proven ability to process data after
        1999. If these deferrals are significant, the Company may not achieve
        expected revenue or earnings levels.

        BALANCE SHEET

        INVESTMENTS

        Investments decreased during the three months ended March 31, 1999 due
        to the Company's reinvestment of maturities in highly liquid investments
        with original maturities of three months or less.


        ACQUIRED TECHNOLOGY

        Acquired Technology increased during the three months ended March 31,
        1999 due to the acquisitions of Intelus and Med Data.


        LONG-TERM DEBT

        Long-term debt increased during the three months ended March 31, 1999
        due to the acquisitions of Intelus and Med Data.

        LIQUIDITY AND CAPITAL RESOURCES

        During the three months ended March 31, 1999, the Company generated $1.3
        million in cash flow from operations. Included in operations is
        approximately $722,000 of costs paid directly related to the poolings of
        Transition and PCS. Additionally the Company paid approximately $5.0
        million of annual employee compensation related liabilities during the
        first quarter. The Company used $27.5 million for investing activities,
        which was primarily the result of the acquisitions of Intelus and Med
        Data. Financing activities provided an additional $21.3 million,
        primarily due to borrowings on the line of credit for the acquisitions
        of Intelus and Med Data.

        As of March 31, 1999, the Company had $20.0 million outstanding under
        its $50.0 million revolving credit facility.

        As of March 31, 1999, the Company had $50.3 million in cash and cash
        equivalents.

        Management believes that its available cash and cash equivalents,
        anticipated cash generated from its future operations and amounts
        available under the existing revolving credit facility will be
        sufficient to meet the Company's operating requirements for at least the
        next twelve months.



<PAGE>   12



        PART II.


        ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K

        (a)    Exhibits:  See Index to exhibits.
        (b)    Reports on Form 8-K: Filed with the Securities and Exchange 
               Commission on January 12, 1999 and March 3, 1999.


<PAGE>   13





                                   SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the
        registrant has duly caused this report to be signed on its behalf by the
        undersigned thereunto duly authorized.



                                                     ECLIPSYS CORPORATION



        Date:  April 13, 1999                  /s/ ROBERT J. VANARIA
                                               ---------------------- 
                                                     Robert J. Vanaria
                                                     Chief Financial Officer




<PAGE>   14




<TABLE>
<CAPTION>
                              ECLIPSYS CORPORATION
                                 EXHIBIT INDEX

        EXHIBIT
           NO.                                            DESCRIPTION
        -------                                            -----------

     <S>        <C>
        2       Stock Purchase and Sale Agreement dated as of March 6. 1999 by
                and among Sungard Data Systems Inc., Sungard Investment
                Ventures, Inc., Med Data Systems, Inc., Intelus Corporation, and
                Eclipsys Corporation and Eclipsys Solutions Corp.

        10.1    Amended and Restated 1998 Employee Stock Purchase Plan, as
                amended

        10.2    1998 Stock Incentive Plan, as amended

        10.3    1999 Stock Incentive Plan

        27      Financial Data Schedule (for SEC use only).
</TABLE>